Aug 23, 2024 Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq Learn More
Aug 13, 2024 Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update Learn More
Aug 8, 2024 Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024 Learn More
Jul 23, 2024 Cellectar Biosciences’ Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom’s Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months Learn More